Search PubMed⌕ Search

Biomedical subjects

Y Yanagawa

Publications and source records attributed to Y Yanagawa.

At least 109 records · Page 6Linked to original sources
PubMed1990

[A successful surgical case report of subaortic stenosis due to accessory mitral valve tissue associated with partial ventricular septal hypertrophy].

One-year- and ten-month-old male infant with subaortic stenosis due to the accessory mitral valve tissue associated with asymmetrical myocardial hypertrophy was treated successfully with surgery. Preoperative diagnosis of "discrete subaortic stenosis" was achieved by echocardiography and angiography. A 70 mmHg of preoperative pressure gradient from left ventricle through ascending aorta could be reduced to 25 mmHg by the operative excision of this accessory mitral valve tissue and partial resection of this septal hypertrophy. This patient was supposed to be complicated with the ventricular septal aneurysm according to the angiographic study, even though this aneurysm was not visualized at the time of the operation. According to our knowledge, only fifteen cases of stenosis due to accessory mitral valve tissue was reported. The pathological findings of the excised specimens of these anomalous tissue were presented and developmental genesis of this intracardiac anomalous tissues, perhaps based on the developmental anomaly of the primitive organ of the endocardial cushion, was discussed in this report.

Aortic Valve Stenosis↗
PubMed1990

[The development of a highly sensitive IgE immunoradiometric assay using monoclonal antibodies].

We have developed two-site immunoradiometric assay (IRMA) for quantitation of human serum IgE, using two different anti-IgE monoclonal antibodies which recognize different epitopes on IgE molecule. We obtained 25 different monoclonal antibodies classified seven groups, and then two different monoclonal antibodies were selected for bead coater and tracer after checking the titer and specificity of each antibody. IgE IRMA we developed here showed good performance in terms of specificity, sensitivity and reproducibility. No cross-reactivity to IgG, IgM and albumin in the level of normal range was observed. The sensitivity for IgE assay was 0.6 x 10(-3) IU/tube and measurable range was 0.01-20.0 IU/tube (0.5-10(3) IU/ml). Coefficient of variations of Intra assay were 2.2-4.3% and average recovery yield was 92.5-108%. Good correlations with Phadebas IgE PRIST and Pharmacia IgE RIA were obtained i.e., y = 1.12x-0.19 (r = 0.96) and y = 0.97x-5.9 (r = 9.7), respectively. These results indicate that the assay system will contribute much to the routine diagnosis for atopic allergy disease and parasitic infections.

Antibodies, Monoclonal↗
PubMed1990

[Bone marrow suppression in gynecological patients with malignant tumor treated with combination chemotherapy cyclophosphamide, pirarubicin and cisplatin].

We treated 14 patients with cyclophosphamide, adriamycin and cisplatin (CAP), and 16 patients with cyclophosphamide, Pirarubicin and cisplatin (CTP). Hematological changes in the peripheral blood were compared in the two groups to determine whether there was any difference in bone marrow suppression. 1) The lowest leukocyte counts were similar in the two groups. The leukocyte count reached its nadir at 11.6 +/- 2.1 days in the CTP group and at 15.1 +/- 2.8 days in the CAP group, a significant difference (p less than 0.01). 2) The leukocyte count recovered rapidly in the CTP group and was significantly higher (p less than 0.01) at 3 to 4 weeks than in the CAP group, and it returned to the pretreatment level in the CTP group in the fourth week. 3) The platelet count reached its lowest level in the second week in both groups. In the CTP group, it was significantly higher (p less than 0.01) than in the CAP group. 4) Reticulocyte count reached its lowest level in the first week in both groups, and then started increasing. 5) In the CTP group, a course of treatment was 28.0 +/- 2.3 days and it was 29.5 +/- 2.3 days in the CAP group. In 28% of the CPA group, it took 30 days or more for the leukocyte count to return to normal after one course, while none of the CTP group did the leukocyte count remain low for 30 days. These results show that CTP causes more rapid bone marrow suppression (particularly leukocytopenia) than CAP, does but that a recovery is more rapid with CTP. These CTP may be a better form of treatment than CAP.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature.

A 53-year-old woman was treated with 5 courses of CAP treatment following operation for FIGO Stage Ia cancer of the ovary in September 1986. And in April 1987, she started an oral adjuvant chemotherapy with 400 mg/day of carmofur. In early June, she developed vertigo and dysarthia and was hospitalized. A CT scan showed low-density areas adjacent to both lateral ventricles, and an EEG revealed abnormally slow waves. She improved gradually after carmofur was discontinued and left the hospital in October 1987. There have been 24 reported cases of leukoencephalopathy because of carmofur in Japan, but the pathophysiological mechanism involved is not known. Since it is more common in women than in men, its incidence will probably increase in gynecological patients. Therefore, we must be on the lookout for central nervous system signs and symptoms in patients receiving adjuvant chemotherapy with carmofur.

Antineoplastic Agents↗
PubMed1989

[Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors].

We concomitantly administered a large dose of medroxyprogesterone acetate (MPA) to gynecological malignant tumor patients undergoing CAP therapy (CAP). Hematological changes in the peripheral blood were compared between concomitant MPA patients and those not receiving MPA to examine the effect of MPA in reducing the marrow depression which is the major side effect of CAP. 1) Leukocyte count reached minimum at the second week of CAP in both groups. There was no significant difference in the count between the two groups. At the third week of CAP, the count improved to 84% of the pre-CAP level in patients receiving MPA and to 68% in those not receiving MPA, a significant difference (p less than 0.01). At the fourth week, leukocyte counts were 105% and 96% of pre-CAP levels, respectively. There was no difference between the two groups, but the leukocyte count returned to the pre-CAP level in the patients receiving MPA. 2) Platelet count showed changes similar to those in the leukocyte count. In patients receiving MPA, the count improved more rapidly within three weeks (118%, p less than 0.01), and was significantly higher at the fourth week (107%, p less than 0.05) than in patients not receiving MPA. 3) Reticulocyte count reached minimum in the first week, thereafter improving rapidly in both groups. No differences were noted between the two groups. 4) The periods needed for one course of CAP were 27.7 +/- 3.3 days in the patients receiving MPA and 29.5 +/- 3.7 days in the patients not receiving MPA, making for a significant difference between the two groups (p less than 0.05). These results show that MPA accelerates recovery from marrow depression caused by CAP. It is anticipated, therefore, that MPA will be helpful in the application of various chemotherapies which are expected to be frequently conducted in the future.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

[Carcinogenesis in familial polyposis coli].

The inherited cancer disease familial polyposis coli (FPC) provides an excellent model not only for studying tumor progression in colorectal cancer but also for elucidating molecular mechanism of carcinogenesis in general. This paper reviews recent remarkable progress in the molecular mechanism of tumorigenesis in FPC. Included in this review is information on the localization of the FPC major gene and several types of genetic alterations during the development of tumors. One of these genetic alterations is activation of oncogenes such as mutated ras genes and another is inactivation of tumor suppression genes such as loss of heterozygosity. The mutated FPC gene on chromosome 5 q would be expected to be an early event to initiate the requisite hyperproliferation for adenoma formation. Adenomas will have undergone several gene or chromosome mutations before reaching the fully malignant state.

Adenomatous Polyposis Coli↗
PubMed1989

[A case of concomitant association of discrete subaortic stenosis in Kelly type I and hypertrophic cardiomyopathy in early stage].

A 1-year-old baby boy with discrete subaortic stenosis in Kelly type I had coexisting echocardiographic evidence for probably indicating the presence of hypertrophic cardiomyopathy in early stage. At surgery, a discrete subaortic "fibrous membrane" was excised: although the thickening of upper ventricular septum was not thought to be so prominent, the prognosis is related to the natural history of hypertrophied muscle despite successful surgical removal of the subaortic diaphragm.

Aortic Stenosis, Subvalvular↗
PubMed1988

A novel sodium channel inhibitor from Conus geographus: purification, structure, and pharmacological properties.

A novel toxin, tentatively named conotoxin GS (CGS), has been isolated from a marine snail, Conus geographus. CGS was found to exist as a single polypeptide chain, consisting of 34 amino acid residues, cross-linked by three disulfide bonds. Its amino acid sequence was shown to be Ala-Cys-Ser-Gly-Arg-Gly-Ser-Arg-Cys-Hyp-Hyp-Gln-Cys-Cys-Met-Gly-Leu-Arg- Cys-Gly - Arg-Gly-Asn-Pro-Gln-Lys-Cys-Ile-Gly-Ala-His-Gla-Asp-Val. In competition experiments, CGS inhibited the bindings of [3H]Lys-tetrodotoxin ([3H]Lys-TTX) and [3H]propionylconotoxin GIIIA to Electrophorus electricus electroplax membranes, with Ki values of 34 nM and 24 nM, respectively. The toxin inhibited the binding of [3H]Lys-TTX (1 nM) to rat skeletal muscle homogenates with an IC50 value of 880 nM but showed very little effect on this binding to the rat brain P2 fraction at 10 microM. These binding studies indicate that CGS belongs to the same group of Na channel inhibitors as TTX, STX (saxitoxin), and mu-conotoxins. Although CGS, like the mu-conotoxins, is a pharmacological probe for distinguishing between neuronal and muscle Na channel subtypes, the homology in the sequences of CGS and mu-conotoxins is very limited.

Amino Acid Sequence↗
PubMed1988

Deletion of a single chromosome band 4q26 in a malformed girl: exclusion of Rieger syndrome associated gene(s) from the 4q26 segment.

We report a malformed girl with a single chromosome band deletion of 4q26 in peripheral lymphocytes. This patient is the fourth case reported with an interstitial deletion involving 4q26 and has the smallest deletion of those reported. Deletion mapping indicates that psychomotor retardation, coloboma, prominent forehead, epicanthus, broad based nose, and broad, thin upper lip are associated with monosomy 4q26, and that gene(s) associated with Rieger syndrome can be excluded from the 4q26 segment.

Abnormalities, Multiple↗
PubMed1988

[The relationship of the occurrence and growth of experimental cervical carcinoma to the local sympathetic nervous system].

An experiment was carried out to clarify the relationship of the occurrence and growth of experimental cervical carcinoma to its surrounding sympathetic nerves. We first examined the effect of sympathetic nerve disturbance on the occurrence and growth of tumors. Using 20-methylcholanthrene (MC), cervical carcinoma was induced in mice, in which the sympathetic nervous system was blocked with 6-hydroxydopamine (6-OH-DA) while a control group received physiological saline. After 16 weeks, the incidence of invasive tumor in the uterine cervix (cervix), the size of the tumor, and the site where the tumor was most likely to occur were compared in two groups. Although the 6-OH-DA group tended to bear a larger tumor, there was no difference in the incidence of invasive tumor or the site where the tumor was most likely to occur. Next, the localization of the sympathetic neurotransmitter norepinephrine (NE) in the cervix was estimated by the fluorescent histochemical method 16 weeks after the insertion of a MC-impregnated thread to determine the effect of cervical carcinoma on sympathetic nervous function in the surrounding tissue. The intensity of fluorescence was reduced around the tumor, and no fluorescence was detected within the tumor. These results were confirmed by the measurement of NE content in the cervix with HPLC. Based on these results, it was revealed that sympathetic nervous disturbance facilitated the growth of experimental cervical carcinoma without influencing its occurrence, and that the sympathetic nerves in the surrounding tissue to cervical carcinoma were damaged by some mechanism of action.

Animals↗
PubMed1988

[Clinical application of rokitamycin in pediatrics].

Rokitamycin (RKM, TMS-19-Q) was used for the treatment of infections in patients with underlying diseases. Many antibiotics are tended to be used on these patients with underlying diseases mainly for prophylactic purposes and, as a consequence, microbes resistant to antibiotics frequently become pathogens in these cases. Responses of our patients to RKM, however, were generally excellent but one who had EB virus infection.

Administration, Oral↗
PubMed1988

[Immunohistochemical studies on epidermal growth factor receptor in experimental squamous cell carcinoma of the uterine cervix of mice].

The tissue localization of epidermal growth factor receptor (EGF-R) in experimental squamous cell carcinoma of the mouse uterine cervix was examined immunohistochemically. Carcinoma was induced by the insertion of a 20-methylcholanthrene (MC)-impregnated thread into the cervical canal of the mouse. Tissue sections (of normal columnar epithelium, proliferation, atypical proliferation, early invasive carcinoma, invasive carcinoma and metastatic carcinoma) were stained by the avidin/biotin immunoperoxidase technique using anti-EGF-R monoclonal antibody. Normal columnar epithelium was negative for EGF-R, whereas proliferation was partly positive. The lesions of atypical proliferation and early invasive carcinoma had a positive staining for EGF-R. The staining for EGF-R declined in the lesion of invasive carcinoma. Metastatic carcinoma was not stained for EGF-R. These results suggest that EGF-R may play an important role in the early stage of carcinogenesis of the mouse uterine cervix induced by 20-MC.

Animals↗
PubMed1988

[EGF receptor and effects of EGF on growth and tumor marker secretion in uterine cervical cancer cells].

Effects of EGF on proliferation and tumor marker secretion of cervical cancer cells are reported together with the characteristics of EGF receptors on the cells. TA-4 producing cell line (OMC-1) originating from cervical squamous cell carcinoma and CA-125 producing cell line (OMC-4) originating from cervical adenocarcinoma, were used. Scatchard plot of EGF binding to OMC-1 indicated a single class of binding sites with a dissociation constant (Kd) of 360pM, whereas that of OMC-4 was curvilinear suggesting two classes of binding sites with a Kd of 170pM and 510pM. The theoretical maximum number of binding sites of OMC-1 and OMC-4 was 2.4 X 10(4) and 1.6 X 10(5), respectively. Effects of EGF on growth were studied by monitoring cell number and the incorporation of 3H-thymidine into the DNA of the cells. OMC-1 was stimulated by EGF at low concentrations (0.01-0.1nM) and inhibited at higher concentrations. OMC-4 was not stimulated by EGF. The TA-4 secretion of OMC-1 was slightly stimulated by EGF at low concentrations (0.01-1nM) and significantly stimulated at high concentration (10nM). The CA-125 secretion of OMC-4 was not stimulated by EGF. These results suggest that there are some differences between cervical squamous cell carcinoma and adenocarcinoma in the mechanisms of regulation of proliferation and tumor marker secretion by EGF.

Adenocarcinoma↗